IQV (IQVIA Holdings) Risk Assessment

View and export this data going back to 2013. Start your Free Trial

What is IQVIA Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of IQVIA Holdings is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of IQVIA Holdings's Risk Assessment

For the Diagnostics & Research subindustry, IQVIA Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IQVIA Holdings's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's Risk Assessment falls into.

Save Embed

;

Save Embed

;

IQVIA Holdings (NYSE:IQV) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

IQVIA Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

IQVIA Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (NYSE:IQV) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

IQV:Mexico 0JDM:UK QTS:Germany I1QV34:Brazil IQVH:Austria

Address

2400 Ellis Road, Durham, NC, USA, 27703

Website

https://www.iqvia.com

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Executives

Eric Sherbet	officer: See Remarks	100 IMS DRIVE, PARSIPPANY NJ 07054-4235
Ari Bousbib	director, officer: Chairman, CEO & Pres	UNITED TECHNOLOGIES CORP, ONE FINANCIAL PLAZA, HARTFORD CT 06101
W Richard Staub	officer: See Remarks
Kevin C Knightly	officer: Pres Info & Tech Solutions	1499 POST ROAD, FAIRFIELD CT 06824
Panagos Constantinos	officer: See Remarks	4280 EMPEROR BLVD, DURHAM NC 27703
Keriann Cherofsky	officer: See Remarks	4280 EMPEROR BLVD, DURHAM NC 27703
Sheila A Stamps	director	C/O CIT GROUP, 1 CIT DRIVE, ATTN: GENERAL COUNSEL, LIVINGSTON NJ 07039
Morris Leslie Wims	director	4280 EMPEROR BLVD, DURHAM NC 27703
John Connaughton	director, 10 percent owner	BAIN CAPITAL PARTNERS LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Ronald E Bruehlman	officer: See Remarks	C/O IQVIA HOLDINGS, INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
Ronald A Rittenmeyer	director	5400 LEGACY DRIVE, PLANO TX 75024
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Michael J Evanisko	director	BRAUN CONSULTING, 20 W KINZIE STREET SUITE 1600, CHICAGO IL 60610
Michael R Mcdonnell	officer: Chief Financial Officer	C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
John M. Leonard	director	C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139